Recurrent High Grade Glioma Clinical Trial
Official title:
Study on Precision Treatment Strategy Through PTCs (Patient-derived Tumor-like Cell Clusters)-Based Drug Screening for Recurrent High-grade Gliomas
This trial is an open-label, single-arm, phase 0/1 study of high-grade glioma that aims to evaluate the feasibility, preliminary efficacy and safety of the precision treatment strategy.
The investigators have established a precision treatment strategy, that select chemotherapeutic drugs or targeted drugs based on information from PTCs drug-screening or/and bioinformatic prediction. In this study, the investigators are going to exploit this strategy for the precision treatment of recurrent high-grade gliomas. The investigators will evaluate the feasibility, safety and preliminary efficacy via collecting the indexes comprising clinical presentation, results of imaging examination, clinical assays, KPS, neurological score, etc. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06161610 -
Recurrent High Grade Glioma Treated by LITT
|
N/A | |
| Active, not recruiting |
NCT03234595 -
A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
|
Phase 1/Phase 2 | |
| Completed |
NCT02567539 -
Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma
|
N/A | |
| Not yet recruiting |
NCT06126744 -
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
|
Phase 1 | |
| Recruiting |
NCT06305910 -
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
|
Phase 1 | |
| Recruiting |
NCT05698524 -
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
|
Phase 1 | |
| Completed |
NCT01172964 -
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
|
Phase 1 |